Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions.
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes, and bleeding. The antiviral drug ribavirin seems to be an effective treatment for Lassa fever if given early on in the course of clinical illness.
The Lassa Fever (Lassa Hemorrhagic Fever) drugs in development market research report provide comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lassa Fever (Lassa Hemorrhagic Fever) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lassa Fever (Lassa Hemorrhagic Fever) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lassa Fever (Lassa Hemorrhagic Fever) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lassa Fever (Lassa Hemorrhagic Fever) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akagera Medicines IncArisan Therapeutics Inc
Auro Vaccines LLC
Curevac NV
Emergent BioSolutions Inc
Fox Chase Chemical Diversity Center Inc
FUJIFILM Toyama Chemical Co Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
GeoVax Labs Inc
Globavir Biosciences Inc
Helix Biogen Institute
ImmunityBio Inc
Imperial College London
Imunon Inc
International AIDS Vaccine Initiative Inc
Kineta Inc
Medigen Inc
Merck & Co Inc
Moderna Inc
OyaGen Inc
RetroVirox Inc
Thomas Jefferson University
Tulane University
University of Oxford
Uvax Bio LLC
Voltron Therapeutics Inc
Zalgen Labs LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lassa Fever (Lassa Hemorrhagic Fever) reports